Abstract
AbstractEpibatidine is a potent analgetic agent with high affinity for nicotinic receptors. The antinociceptive effects of epibatidine are blocked by both competitive and noncompetitive nicotinic antagonists. The L‐type calcium channel activator Bay K 8644 potentiates the antinociceptive effects of epibatidine, while nifedipine antagonizes the antinociceptive effects. Acute treatment with chlorisondamine leads to long‐term blockade of the antinociceptive effects of epibatidine. The antinociceptive effects of epibatidine are reduced in mice rendered tolerant to the behavioral effects of nicotine by chronic nicotine or caffeine treatment. Epibatidine has very high affinity for the major central nicotinic receptor to which [3H]nicotine binds. However, unlike nicotine and cytisine, epibatidine is very potent at ganglionic‐type nicotinic receptors. Epibatidine in cultured cells causes desensitization of both ganglionic and neuromuscular nicotinic receptors. Thus, like nicotine, chronic treatment with epibatidine might be expected to lead to tolerance. These studies establish epibatidine as a tool for the study of nicotinic pathways involved in pain perception. © 1995 Wiley‐Liss, Inc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
